Shingles Vaccine & Dementia Risk: New Research
- The shingles vaccine may offer protection beyond preventing a painful outbreak.Emerging research suggests it could also lower the risk of developing dementia.
- A 2025 study by Welsh researchers found that older adults who received the Zostavax vaccine were 20% less likely to develop dementia over seven years, compared to those...
- A 2024 British study comparing the two vaccines over six years indicated that shingrix might potentially be even more effective.
Breaking news: New research highlights a potential link between the shingles vaccine and a reduced risk of dementia. This study reveals that the primary_keyword shingles vaccine, targeting the varicella-zoster virus, may offer benefits beyond preventing painful outbreaks, possibly influencing secondary_keyword cognitive health years later. Findings from various studies show promising results, with some suggesting those vaccinated against shingles had a substantially lower chance of developing dementia. The article dives into potential mechanisms, from viral reactivation to immune system modulation. This news, brought to you by News Directory 3, could change how we view preventative healthcare.Discover what’s next in this evolving field.
Shingles Vaccine Linked to Lower Dementia Risk
Updated June 18, 2025
The shingles vaccine may offer protection beyond preventing a painful outbreak.Emerging research suggests it could also lower the risk of developing dementia. Shingles is caused by the varicella-zoster virus, the same virus responsible for chickenpox. After a chickenpox infection, the virus lies dormant in nerve cells and can reactivate later in life as shingles.
A 2025 study by Welsh researchers found that older adults who received the Zostavax vaccine were 20% less likely to develop dementia over seven years, compared to those who were unvaccinated.
zostavax is being replaced by Shingrix, a newer vaccine. A 2024 British study comparing the two vaccines over six years indicated that shingrix might potentially be even more effective. The Shingrix group had a 17% lower risk of dementia diagnosis compared to the Zostavax group. Researchers estimated that Shingrix provided 164 extra dementia-free days for those who later developed the condition.
Further supporting this link, a 2024 meta-analysis of five studies, encompassing over 103,000 vaccinated individuals, revealed a consistent association between the herpes zoster vaccine and reduced dementia risk.
The exact mechanism behind this potential benefit remains unclear. Scientists propose several theories:
- Reduction of viral reactivation: Preventing shingles may reduce inflammation or damage to the nervous system caused by the reactivated virus.
- Immune system modulation: The vaccine’s immune-boosting properties might protect the brain by reducing chronic inflammation or clearing harmful proteins.
- Prevention of amyloid formation: some research suggests the virus reactivation can trigger the formation of amyloid proteins, a hallmark of Alzheimer’s disease.
If you are considering getting vaccinated against shingles, these findings provide another compelling reason to do so. The shingles vaccine and dementia prevention may be linked.
What’s next
Further research is needed to fully understand the connection between the shingles vaccine and dementia risk, and to determine the long-term impact of vaccination on cognitive health.